Pharmaceutical composition comprising IL-34 and a mTOR inhibitor

Patent metadata

Field	Value
Publication number	US-11090362-B2
Application number	US-201816174837-A
Country	US
Kind code	B2
Filing date	Oct 30, 2018
Priority date	Jul 17, 2014
Publication date	Aug 17, 2021
Grant date	Aug 17, 2021

Abstract

The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising, in combination, a therapeutically effective amount of an isolated interleukin-34 (IL-34) polypeptide and a suboptimal dose of a mammalian target of rapamycin (mTOR) inhibitor, wherein the suboptimal dose is a dose, which, by itself, does not produce a statistically significant therapeutic effect.

2. The pharmaceutical composition according to claim 1 , wherein the mTOR inhibitor is rapamycin (sirolimus).

3. The pharmaceutical composition of claim 1 , wherein the IL34 polypeptide has a sequence comprising the sequence as set forth in SEQ ID NO: 1.

4. A method of treating autoimmune diseases comprising the step of administering to a patient in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 1 .

Assignees

• Inst Nat Sante Rech Med
• Univ Nantes

Inventors

• Guillonneau Carole
• Anegon Ignacio
• Bezie Séverine

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• G01N33/564

  for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9} · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title